Perihilar Cholangiocarcinoma (pCCA) — also known as the Klatskin tumor after Gerald Klatskin who characterized this biliary malignancy in 1965, representing the most anatomically complex bile duct cancer arising at or near the confluence of the right and left hepatic ducts at the hepatic hilum, comprising approximately 50–60% of all cholangiocarcinomas and the most common anatomical subtype, with an estimated annual United States incidence of 4,000–6,000 new cases, male predominance, median age at diagnosis of 65–70 years, and internationally recognized as the most surgically demanding gastrointestinal malignancy due to the proximity of the biliary confluence to the portal vein bifurcation, hepatic artery bifurcation, and caudate lobe bile ducts — presents with obstructive jaundice (95–99% of patients) as the nearly universal presenting symptom reflecting biliary confluence obstruction, accompanied by pruritus (60–70%), pale stools and dark urine (cholestasis), weight loss (40–50%), fatigue, and episodic cholangitis with fever, chills, and right upper quadrant pain from biliary stasis; classified by the Bismuth-Corlette system based on involvement of the biliary confluence and hepatic ducts — Type I (below the hepatic duct confluence), Type II (at the hepatic duct confluence), Type IIIa (extends to the right secondary hepatic ducts), Type IIIb (extends to the left secondary hepatic ducts), and Type IV (bilateral involvement of secondary ducts or Type I/II with monolobar atrophy and contralateral involvement) — which determines operative approach, extent of hepatic resection, and resectability assessment; risk factors include primary sclerosing cholangitis (PSC, the dominant risk factor in Western series, accounting for 10–40% of pCCA and carrying 10–20% lifetime cumulative risk), choledochal cysts (especially Todani type IV and type I with intrahepatic extension), congenital hepatic fibrosis, Caroli disease, hepatolithiasis with biliary stasis, liver fluke infection (Opisthorchis viverrini, Clonorchis sinensis), inflammatory bowel disease through the PSC pathway, and chronic biliary inflammation from any etiology. Pathologically, pCCA is a poorly to moderately differentiated adenocarcinoma with prominent perineural invasion, lymphovascular invasion, and desmoplastic stromal reaction; immunohistochemically CK7, CK19, CA19-9, EMA, and MUC1 positive with CDX2 negative reflecting biliary rather than intestinal phenotype; molecular landscape includes TP53 (50–60%), KRAS (25–40%), SMAD4 (35–45%), CDKN2A/B (30–40%), ARID1A (15–20%), ROBO1/2 (15%), and low frequency actionable alterations: FGFR2 fusions (3–7% in pCCA, lower than iCCA), IDH1 mutations (3–5%), ERBB2/HER2 amplification (5–10%), BRAF V600E (3–5%), NTRK fusions (2–3%), and MSI-H (5–7%); while actionable alteration frequency is lower in pCCA than iCCA, comprehensive genomic profiling is essential given the therapeutic impact of pemigatinib, ivosidenib, trastuzumab-based regimens, and pembrolizumab for eligible patients. Resectability assessment for pCCA requires evaluation of the Bismuth-Corlette classification for biliary extent, portal vein involvement (ipsilateral portal vein involvement ± reconstruction is potentially resectable, bilateral portal vein involvement is not), hepatic artery involvement, contralateral lobe atrophy (ipsilateral lobe atrophy from ipsilateral portal vein occlusion predicts inadequate FLR from contralateral lobe alone), and future liver remnant (FLR) — portal vein embolization (PVE) of the hemiliver to be resected is required in >60% of pCCA patients to achieve adequate FLR before extended hepatectomy, with repeat FLR volumetric MRI at 4–6 weeks post-PVE required before hepatectomy scheduling; surgical resection requires extended hepatectomy (right or left, with caudate lobe resection in >80% because the caudate lobe bile ducts drain directly into the confluence and near-universally harbor cancer), bile duct resection to the secondary hepatic duct level, biliary reconstruction by hepaticojejunostomy (Roux-en-Y), and is achieved in only 20–40% of patients at presentation with 5-year OS of 30–40% for R0 resection. Liver transplantation for unresectable pCCA (the Mayo Clinic protocol with neoadjuvant chemoradiation followed by orthotopic liver transplantation for unresectable but locally contained pCCA without extrahepatic disease and hilar width <3 cm) achieves 65–72% 5-year OS in select PSC-pCCA patients. Systemic therapy for unresectable or metastatic pCCA — first-line gemcitabine-cisplatin-durvalumab (TOPAZ-1) and molecularly directed second-line therapy identical to iCCA and distal eCCA management — must be delivered with careful attention to the biliary drainage optimization required for cisplatin eligibility in a population where biliary obstruction from the hilar lesion persistently compromises GFR and bilirubin clearance.
pCCA technology platforms — whether supporting hepatobiliary oncology programs coordinating gemcitabine-cisplatin-durvalumab with careful biliary drainage optimization for the near-universal biliary obstruction (managing bilateral biliary stents for Bismuth III/IV lesions via ERCP or PTBD, bilirubin ≤1.5× ULN verification before each cisplatin cycle, CA19-9 and biliary tumor markers, and RECIST CT at baseline and every 2–3 cycles), PSC surveillance programs performing annual MRCP and brush cytology FISH for pCCA surveillance in PSC patients, molecular profiling laboratories performing comprehensive genomic profiling for FGFR2 fusion detection and IDH1 mutation sequencing in the smaller fraction of actionable pCCA cases, HPB surgical platforms managing the technically extreme extended hepatectomy with caudate lobe resection and biliary reconstruction — including portal vein embolization scheduling, serial FLR volumetric MRI, portal vein reconstruction operative planning, and caudate lobe bile duct margin frozen section pathology — liver transplantation evaluation platforms coordinating the Mayo Protocol neoadjuvant chemoradiation and transplant listing for select unresectable PSC-pCCA patients, locoregional therapy platforms managing transarterial radioembolization (TARE/Y-90), stereotactic body radiotherapy (SBRT), and photodynamic therapy (PDT) for unresectable pCCA, and biliary drainage platforms managing bilateral percutaneous biliary drains for ERCP-inaccessible hilar obstruction — must maintain the availability and performance standards that pCCA's universal biliary obstruction, surgically extreme resection logistics, Mayo Protocol transplantation coordination, cisplatin eligibility requirements, molecular profiling requirements, and PSC surveillance obligations demand. This guide explains why pCCA tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the biliary drainage, surgical, transplantation, systemic therapy, and PSC surveillance complexity of modern Klatskin tumor management.
Why pCCA Tech Platforms Require Specialized Monitoring Attention
pCCA management is defined by the biliary drainage complexity of hilar obstruction — where bilateral metal stent placement for Bismuth III/IV lesions via ERCP or PTBD is a technically demanding intervention repeated multiple times across the disease course, where stent failure causes cholangitis and biliary sepsis with particular severity in patients on durvalumab immunosuppression, and where bilirubin optimization for cisplatin eligibility requires continuous biliary surveillance — the FLR volumetric assessment obligation for the majority of pCCA patients requiring portal vein embolization where MRI volumetry must confirm adequate FLR before hepatectomy can be scheduled, the caudate lobe resection and biliary reconstruction complexity demanding the highest tier of HPB surgical and intraoperative pathology coordination, the PSC surveillance obligation for the large fraction of pCCA arising in PSC patients where annual MRCP and brush cytology scheduling must be maintained within the surveillance window, and the Mayo Protocol liver transplantation coordination for select unresectable PSC-pCCA patients where neoadjuvant chemoradiation scheduling and transplant waitlist management require continuous multidisciplinary platform access.
Bilateral biliary drainage platforms are the highest-urgency pCCA platform component. Bismuth III/IV pCCA with bilateral intrahepatic duct obstruction — where bilateral metal stent placement via ERCP (side-by-side or stent-in-stent technique) or bilateral PTBD external-internal drains maintains hepatic bile drainage and prevents cholangitic hepatic abscesses — requires the most intensive biliary stent surveillance of any biliary malignancy given the anatomical complexity of bilateral hilar stenting, the frequency of right versus left lobe stent failure, and the PSC-confounded baseline hepatic function making cholangitis decompensation faster in PSC-pCCA than non-PSC pCCA. Monitor bilateral biliary drainage platforms at 1-minute intervals during clinical hours with 24/7 cholangitis critical alerting.
FLR volumetric and portal vein embolization platforms determine surgical resectability timing. Portal vein embolization — where PVE of the right portal vein before right extended hepatectomy for Bismuth IIIa pCCA induces left lobe hypertrophy over 4–6 weeks to achieve FLR/TLV ≥25–40% — requires serial FLR MRI volumetric reassessment at 4 and 6 weeks post-PVE, with hepatectomy scheduling contingent on FLR volumetric adequacy and liver function reserve confirmation; a platform failure preventing FLR re-measurement at the 4-week PVE window delays the hepatectomy scheduling that is time-critical for a patient with resectable pCCA where tumor progression during PVE hypertrophy waiting may compromise resectability. Monitor FLR volumetric platforms at 1-minute intervals during business hours.
Mayo Protocol transplantation coordination platforms require continuous multidisciplinary availability. The Mayo Clinic neoadjuvant protocol for unresectable pCCA — where PSC-pCCA patients meeting protocol criteria (unresectable disease, lesion <3 cm radial diameter, no extrahepatic disease, no prior upper abdominal surgery) receive external beam radiation (45 Gy in 30 fractions) with concurrent fluorouracil infusion, an intraluminal brachytherapy boost, and maintenance oral capecitabine while listed for orthotopic liver transplantation — requires transplant center, radiation oncology, and hepatology platform coordination across the 6–12-month pretransplant period where protocol staging assessments (transperitoneal biopsy exclusion, laparoscopic staging to exclude peritoneal disease), waitlist management, and pretransplant liver function monitoring all require simultaneous platform access. Monitor Mayo Protocol transplant coordination platforms at 1-minute intervals during business hours.
What to Monitor on a pCCA Tech Platform
Bilateral Biliary Drainage and Stent Management
Monitor ERCP bilateral metal stent placement records (right and left intrahepatic duct access documentation, stent diameter and length, fluoroscopic and cholangiographic documentation), PTBD bilateral external-internal drain records for ERCP-inaccessible Bismuth III/IV obstruction (right and left lobe drain separately managed with individual output volumes and character), total bilirubin with ≥3× ULN threshold alerting for bilateral stent failure — noting that total bilirubin imperfectly reflects bilateral drain function where unilateral right or left stent failure may produce right or left lobe atrophy before bilirubin rises critically — alkaline phosphatase, GGT, direct bilirubin for ongoing biliary disease activity, cholangitis clinical assessment with biliary sepsis protocol triggers, right and left intrahepatic duct dilatation ultrasound or CT assessment for stent patency, stent exchange scheduling (bilateral metal stent exchange by percutaneous route when stents occlude), and PTBD drain replacement records at 1-minute intervals during clinical hours with 24/7 bilateral biliary sepsis alerting. Alert immediately — bilateral biliary drainage platform failures in Bismuth III/IV pCCA prevent the real-time coordination between the biliary intervention team and the oncology team that determines whether a patient's rising bilirubin reflects bilateral stent failure (requiring urgent IR and endoscopy mobilization for bilateral stent exchange) versus disease progression (requiring systemic therapy reassessment).
Gemcitabine-Cisplatin-Durvalumab Administration and Biliary Eligibility Verification
Monitor pre-cycle CBC with differential, comprehensive metabolic panel with bilirubin ≤1.5× ULN for gemcitabine eligibility and GFR ≥60 mL/min for cisplatin eligibility — noting the persistent challenge in pCCA patients where bilateral hilar stenting imperfectly normalizes bilirubin, requiring individualized bilirubin threshold decisions negotiated between oncology and gastroenterology for patients in whom maximum biliary drainage has been achieved but bilirubin remains 1.5–3× ULN — magnesium supplementation and IV hydration documentation, gemcitabine (1000 mg/m²) and cisplatin (25 mg/m²) day 1 and day 8 preparation records, durvalumab (1500 mg) day 1 preparation records, immune-related adverse event surveillance with particular attention to durvalumab hepatitis in the context of PSC-related hepatic disease where baseline elevated alkaline phosphatase and bilirubin confound immune hepatitis diagnosis, CA19-9 pre-cycle trending, and cycle delay and dose reduction documentation at 1-minute intervals during infusion days. Alert immediately — gemcitabine-cisplatin-durvalumab platform failures during the biliary eligibility verification process for a pCCA patient whose bilateral PTBD drains have reduced bilirubin from 8.4 to 2.1 mg/dL and whose oncologist is confirming borderline cisplatin eligibility disrupt the treatment-day decision workflow where the pharmacist has already begun drug preparation.
Portal Vein Embolization and FLR Volumetric Assessment
Monitor portal vein embolization procedure records (right portal vein embolization approach — percutaneous transhepatic ipsilateral approach, contralateral approach, or transileocolic approach — embolization material, post-PVE completion angiography), FLR volumetric MRI at baseline (pre-PVE), 4 weeks post-PVE, and 6 weeks post-PVE with FLR/TLV ratio documentation and hypertrophy degree calculation (hypertrophy degree = [FLR post-PVE − FLR pre-PVE] / FLR pre-PVE × 100%), minimum FLR threshold documentation (≥25% for normal liver, ≥35% for PSC cirrhosis, ≥40% for Child-Pugh B), kinetic growth rate calculation for inadequate hypertrophy identification, liver function reserve assessment (indocyanine green retention at 15 minutes, Child-Pugh, MELD-Na), and hepatectomy scheduling contingent on FLR volumetric confirmation at 1-minute intervals during business hours. Alert immediately — FLR volumetric platform failures at the 4-week or 6-week post-PVE assessment delay hepatectomy scheduling for resectable pCCA where a 2–4 week delay in hypertrophy assessment can extend the total PVE-to-hepatectomy interval into the window where local tumor progression compromises portal vein or hepatic artery proximity and converts a resectable case to unresectable.
Extended Hepatectomy with Caudate Lobe Resection
Monitor extended hepatectomy operative records including right or left extended hepatectomy extent (Couinaud segments resected), caudate lobe resection documentation (segment I complete resection confirmed), porta hepatis dissection records, bile duct transection level (right and/or left secondary hepatic ducts) with intraoperative cholangiography, bile duct margin frozen section results from intraoperative pathology (right and left bile duct margins × 2–4 sections per side), portal vein proximity records and portal vein resection and reconstruction records when required, hepatic artery proximity documentation and reconstruction records when required, Roux-en-Y hepaticojejunostomy construction records, operative blood loss and transfusion, Pringle maneuver duration and ischemia time, abdominal drain placement, and post-hepatectomy day-5 bilirubin and INR for 50-50 criteria (bilirubin >50 μmol/L [2.9 mg/dL] AND INR >50%) identifying post-hepatectomy liver failure at 1-minute intervals during operative and post-operative sessions. Alert immediately — extended hepatectomy platform failures at the moment of intraoperative bile duct margin frozen section review — where the HPB surgeon decides between accepting a positive margin and extending the resection to the secondary confluence level, and the operative decision requires immediate pathology communication — cannot be interrupted by laboratory information system unavailability when the operative margin decision determines R0 versus R1 status.
Mayo Protocol Liver Transplantation Coordination
Monitor neoadjuvant protocol staging assessment records (staging laparoscopy to exclude peritoneal disease, transperitoneal biopsy exclusion documentation — endobiliary biopsy and cytology only, no transperitoneal needle biopsy as a protocol requirement for transplant eligibility), external beam radiation (45 Gy in 30 fractions to the tumor and regional lymphatics) treatment scheduling and delivery records with concurrent fluorouracil infusion, intraluminal brachytherapy boost dosimetry records, maintenance capecitabine prescription and dose documentation, transplant listing records (UNOS status, waitlist priority, HCC exception extension protocols for pCCA), protocol restaging at 6 months and annually with MRCP, cross-sectional CT, and staging laparoscopy before transplant to confirm absence of extrahepatic disease progression, liver function monitoring on the transplant waitlist, and orthotopic liver transplantation operative records and post-transplant immunosuppression protocols at 1-minute intervals during protocol phases. Alert immediately — Mayo Protocol platform failures during the pretransplant staging assessment window delay the restaging laparoscopy required to confirm ongoing transplant eligibility for a PSC-pCCA patient approaching deceased donor transplant offer, where protocol exclusion criteria evolve with disease duration.
Comprehensive Genomic Profiling and Molecular Targeting
Monitor comprehensive genomic profiling result routing for the 20–30% of pCCA with actionable alterations: FGFR2 fusions (3–7%, lower than iCCA), IDH1 R132 mutations (3–5%), ERBB2/HER2 amplification (5–10%), BRAF V600E (3–5%), MSI-H/dMMR (5–7%), NTRK fusions (2–3%), and RET fusions (<2%), with turnaround time tracking from tissue submission (ERCP biliary brush cytology, PTBD brush or forceps biopsy, cholangioscopic biopsy, or surgical resection specimen) to report delivery, tissue adequacy tracking for CGP (biliary brush cytology cellularity is frequently insufficient for comprehensive NGS, requiring multiple ERCP passes or cholangioscopic biopsy), and molecular profiling report routing to the treating oncologist and tumor board at 1-minute intervals during business hours. Alert immediately — CGP platform failures delay targeted therapy eligibility determination for the minority of pCCA patients with actionable alterations where pemigatinib, ivosidenib, or pembrolizumab eligibility represents the only second-line option after gemcitabine-cisplatin-durvalumab progression.
CA19-9 and Biliary Disease Activity Monitoring
Monitor CA19-9 with pre-cycle measurement and trend line documentation accounting for PSC-related confounding and biliary drainage adequacy affecting CA19-9 production — where post-biliary drainage CA19-9 baseline (obtained after bilirubin normalization) is more reliable than pre-drainage CA19-9 for treatment response monitoring — Lewis antigen-negative false negative documentation, alkaline phosphatase, GGT, direct and total bilirubin trending for ongoing biliary disease activity, CA19-9 ≥20% decline from post-drainage baseline as favorable response indicator, CA19-9 ≥20% rise above nadir as progressive disease indicator with imaging-confirmed response integration, and PSC-specific interpretation guidelines for CA19-9 >130 U/mL thresholds at 2-minute intervals during business hours. Alert on sustained failures — CA19-9 trending platform failures prevent the oncologist from detecting the rising CA19-9 trend that precedes CT-confirmed pCCA progression by 4–8 weeks, eliminating the window for biliary drainage re-optimization and systemic therapy reassessment before performance status decline.
MRCP and Cross-Sectional Biliary Imaging
Monitor MRCP scheduling for biliary anatomy mapping at baseline, post-biliary drainage, pre-operative, and at disease reassessment intervals, CT chest-abdomen-pelvis with biliary protocol at baseline and every 2–3 cycles for RECIST 1.1 response assessment, PET-CT for peritoneal or hepatic lesion characterization and Mayo Protocol restaging, FLR volumetric MRI series scheduling in the portal vein embolization pathway, MRCP for PSC surveillance integration, and biliary anatomy mapping for bilateral stent placement guidance at 1-minute intervals during business hours. Alert immediately — MRCP and CT platform failures during the pCCA surgical evaluation phase delay the key imaging assessments on which the HPB tumor board determines resectability, Bismuth-Corlette classification, and PVE indication.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. pCCA programs are among the most multidisciplinary in oncology, coordinating hepatobiliary oncology, hepatobiliary surgery, interventional endoscopy (ERCP bilateral biliary stenting), interventional radiology (PTBD bilateral drainage, TARE, PVE), hepatology (PSC, liver transplant evaluation, Child-Pugh assessment), transplant surgery (Mayo Protocol), radiation oncology (neoadjuvant EBRT, brachytherapy), molecular pathology (CGP on biliary brush cytology), nutrition, pharmacy, and palliative care — authentication failures simultaneously block the entire pCCA multidisciplinary team at the moment of critical decisions including bilateral biliary reintervention during cholangitis, FLR volumetric resectability determination, and Mayo Protocol restaging before transplant listing.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, transplant registry platforms, molecular profiling platforms, imaging systems, pharmacy systems, biliary drainage surveillance platforms, and radiation oncology treatment planning systems. Certificate errors disrupt gemcitabine-cisplatin-durvalumab eligibility verification, FLR volumetric access, bilateral biliary stent patency monitoring, Mayo Protocol staging documentation, and molecular profiling result routing workflows.
HIPAA and Oncology Data Privacy Considerations
pCCA technology platforms handle extremely sensitive PHI including Mayo Protocol transplantation eligibility documentation with transplant waitlist implications, PSC-related hepatic disease records with insurance and employment implications, bilateral PTBD drain management records with interventional radiology procedure documentation, comprehensive genomic profiling results from biliary brush cytology specimens, Bismuth-Corlette classification and resectability determination records with HPB surgical operative planning, portal vein embolization and extended hepatectomy operative records with liver remnant and surgical margin documentation, neoadjuvant chemoradiation treatment records, and post-transplant immunosuppression records. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing bilateral biliary drainage critical results — where rising bilirubin in the right intrahepatic duct distribution with fever and right upper quadrant pain indicates right lobe cholangitic abscess from unilateral right metal stent occlusion in a patient with bilateral Bismuth IIIa stenting — availability standards must ensure that unilateral stent failure differentiation from bilateral failure and the biliary sepsis clinical protocol are accessible to the IR and endoscopy teams managing pCCA biliary emergencies without platform-imposed delays. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for the most complex biliary oncology programs managing pCCA's intersection of bilateral biliary drainage, HPB surgery, liver transplantation, PSC surveillance, and systemic therapy PHI.
Alerting Strategy for pCCA Tech Platforms
Immediate 24/7 alerting: Bilateral biliary drainage critical-value systems — bilirubin ≥3× ULN, unilateral or bilateral stent failure flags, cholangitis clinical triggers, PTBD drain output cessation alerts. These cannot fail without biliary sepsis risk escalation.
Immediate alerting during treatment sessions: Gemcitabine-cisplatin-durvalumab infusion platforms, neoadjuvant EBRT sessions, extended hepatectomy and PVE procedural sessions, PTBD drain exchange sessions.
Immediate business-hours alert: Comprehensive genomic profiling result routing, CA19-9 biliary tumor marker trending, MRCP and CT RECIST response assessment, FLR volumetric post-PVE assessment, Mayo Protocol staging assessment scheduling, and cisplatin biliary eligibility verification. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Post-hepatectomy and post-transplant surveillance imaging scheduling, photodynamic therapy scheduling, tumor registry documentation, and patient communication portals.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms pCCA platform availability from the geographies where Mayo Protocol transplant programs, high-volume Klatskin tumor HPB surgery programs, and PSC-specialized hepatology centers concentrate — essential for patients whose Mayo Protocol transplant eligibility or resectability assessment requires platform availability at the moment of HPB tumor board decision-making.
Status Page for pCCA Care Team Communication
A real-time status page gives hepatobiliary oncologists managing gemcitabine-cisplatin-durvalumab cycles with biliary drainage optimization, HPB surgeons reviewing FLR volumetrics before extended right hepatectomy, hepatologists managing PSC waitlist patients under Mayo Protocol, interventional radiologists managing bilateral PTBD drains, transplant coordinators monitoring neoadjuvant chemoradiation protocol completion, and molecular pathologists routing CGP results from cholangioscopic biopsies immediate platform visibility without requiring inbound IT support contact. During a bilateral biliary drainage platform outage where a Bismuth IIIb pCCA patient on cycle 3 gemcitabine-cisplatin-durvalumab presents with bilirubin rising from 1.8 to 6.4 mg/dL and right upper quadrant pain suggesting right PTBD drain malfunction, a status page enables the oncology team to activate the bilateral biliary emergency protocol — routing to IR for urgent right drain check and exchange — without platform-dependent delay.
Include the status page URL in bilateral biliary drainage emergency procedures, gemcitabine-cisplatin infusion downtime procedures, extended hepatectomy surgical planning emergency access protocols, Mayo Protocol transplant restaging fallback procedures, and molecular profiling result routing contingency procedures.
Vigilmon Setup for pCCA Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Bilateral biliary drainage / bilirubin critical-value | 1 min | Slack + PagerDuty (24/7) | | PTBD drain output monitoring | 1 min | Slack + PagerDuty (24/7) | | Gemcitabine-cisplatin-durvalumab infusion (treatment days) | 1 min | Slack + PagerDuty (infusion hours) | | FLR volumetric MRI post-PVE | 1 min | Slack + PagerDuty (business hours) | | Comprehensive genomic profiling result routing | 1 min | Slack + PagerDuty (business hours) | | CA19-9 / biliary tumor marker trending | 2 min | Slack + PagerDuty (business hours) | | MRCP / CT RECIST response assessment | 1 min | Slack + PagerDuty (business hours) | | Mayo Protocol staging assessment scheduling | 1 min | Slack + PagerDuty (business hours) | | Extended hepatectomy / PVE procedural session | 1 min | Slack + PagerDuty (operative hours) | | Neoadjuvant EBRT / brachytherapy session | 1 min | Slack + PagerDuty (treatment hours) | | Surveillance imaging (post-hepatectomy / post-transplant) | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure bilateral biliary drainage critical-value platforms with 24/7 immediate alerting for bilateral cholangitis risk
- Add PTBD bilateral drain output monitoring with 24/7 alerting for drain cessation
- Configure gemcitabine-cisplatin-durvalumab infusion platforms with immediate treatment-hours alerting
- Add FLR volumetric MRI post-PVE platforms with immediate business-hours alerting
- Configure comprehensive genomic profiling result routing with immediate business-hours alerting
- Add CA19-9 and biliary tumor marker trending with sustained-failure alerting noting PSC and biliary drainage confounders
- Configure MRCP and CT RECIST response assessment platforms with immediate business-hours alerting
- Add Mayo Protocol staging assessment scheduling and restaging documentation platforms with immediate business-hours alerting
- Configure extended hepatectomy, caudate lobe resection, and PVE procedural session platforms with immediate operative-hours alerting
- Add neoadjuvant EBRT and brachytherapy session platforms with immediate treatment-hours alerting
- Enable SSL certificate monitoring across all clinical, transplant registry, molecular profiling, imaging, pharmacy, and biliary drainage domains
- Add the status page URL to bilateral biliary drainage emergency procedures, gemcitabine-cisplatin downtime procedures, HPB surgical planning emergency protocols, and Mayo Protocol transplant staging fallback procedures
Conclusion
pCCA technology platforms are embedded in clinical decisions where bilateral biliary drainage platform availability during a Bismuth IIIa Klatskin tumor presentation — where the interventional endoscopist coordinating simultaneous right and left intrahepatic duct metal stent placement in a patient with total bilirubin of 16.8 mg/dL, alkaline phosphatase of 920 U/mL, and CT-documented bilateral intrahepatic duct dilatation to segment-level ducts requires real-time fluoroscopic imaging documentation, contrast injection biliary mapping, and stent inventory access for the first biliary drainage procedure that will determine cisplatin eligibility and hepatectomy planning — cannot fail when the clinical consequence of failed bilateral stent placement includes unilateral biliary decompression, ongoing left lobe cholestasis, impaired FLR from contralateral hypertrophy delay, and cisplatin ineligibility from persistent bilirubin elevation; where FLR volumetric platform availability at the 4-week post-PVE assessment — where the HPB surgeon reviewing the MRI volumetric report confirms left lobe hypertrophy from 28.4% to 37.1% FLR/TLV, confirming adequate FLR for right extended hepatectomy with caudate lobe resection in a 63-year-old patient with Bismuth IIIa pCCA and no PSC, and schedules the extended right hepatectomy for 2 weeks hence — cannot fail when the hepatectomy scheduling decision requires volumetric data that, if unavailable, extends the PVE-to-hepatectomy interval into the window where tumor progression at the portal vein bifurcation may render the patient unresectable; and where Mayo Protocol transplant restaging platform availability — where the transplant hepatologist reviewing the annual restaging assessment for a 52-year-old PSC-pCCA patient with 18 months of waitlist accrual and CA19-9 rising from 140 to 240 U/mL requires MRCP, CT chest-abdomen-pelvis, and staging laparoscopy scheduling to confirm absence of peritoneal disease before a projected deceased donor transplant offer — cannot be delayed by scheduling platform unavailability when Mayo Protocol exclusion at restaging eliminates the patient's only curative option with 65–72% 5-year OS versus 5–10% 5-year OS for unresectable non-transplant pCCA. A bilateral biliary drainage platform that prevents stent failure critical-value recognition during right lobe cholangitis, an FLR volumetric platform that delays post-PVE hypertrophy confirmation past the surgical resectability window, a Mayo Protocol staging platform that delays restaging laparoscopy before transplant offer — these are not IT incidents. They are clinical disruptions in the management of the most surgically complex bile duct malignancy, whose universal bilateral biliary obstruction, surgically extreme caudate lobe resection demands, Mayo Protocol transplant coordination, and PSC surveillance obligations make bilateral biliary drainage, FLR volumetric, and transplant staging platform availability directly relevant to resectability, transplant eligibility, and patient survival.
Uptime monitoring gives pCCA tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to hepatobiliary oncology programs, PSC hepatology centers, HPB surgery programs, liver transplant programs, molecular profiling laboratories, bilateral biliary intervention endoscopy and IR services, and compliance auditors that platform operational reliability matches the bilateral biliary drainage urgency, FLR volumetric resectability timing, Mayo Protocol transplant coordination requirements, and PSC surveillance obligations of modern Klatskin tumor management.
Start monitoring your perihilar cholangiocarcinoma care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #perihilarcholangiocarcinoma #Klatskin #pCCA #cholangiocarcinoma #bileductcancer #PSC #BismuthCorlette #ERCP #PTBD #bilateralbiliarydrainage #portallveinembolization #FLR #extendedhepatectomy #caudateloberesection #MayoProtocol #livertransplant #FGFR2 #IDH1 #gemcitabine #cisplatin #durvalumab #CA19-9 #MRCP #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre